Tatsuhiko Fujimoto

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsuhiko Fujimoto. Retrieved from https://idiyas.com/inventor/tatsuhiko-fujimoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 91.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 70(Granted Patents)

Location History:

Fujisawa, JP (2016)
Kanagawa, JP (2015 - 2024)

Company Filing History:

12 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2015-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12281073 - Substituted piperidine compound and use thereof (2025-04-21),

2. 12077522 - Heterocyclic compound and application thereof (2024-09-03),

3. 11319286 - Heterocyclic compound and application thereof (2022-05-03),

4. 11292766 - Substituted piperidine compound and use thereof (2022-04-05),

5. 10898737 - Substituted piperidine compound and use thereof (2021-01-26),

6. 10689373 - 1,2-substituted cyclopentanes as orexin receptor antagonists (2020-06-23),

7. 10508083 - Substituted piperidine compound and use thereof (2019-12-17),

8. 10287305 - Substituted piperidine compound and use thereof (2019-05-14),

9. 10011588 - 1,2-substituted cyclopentanes as orexin receptor antagonists (2018-07-03),

10. 9790220 - Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists (2017-10-17),

11. 9493432 - Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders (2016-11-15),

12. 9156829 - Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists (2015-10-13),

Title: Innovations of Tatsuhiko Fujimoto

Introduction

Tatsuhiko Fujimoto is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target orexin receptors. With a total of 12 patents to his name, Fujimoto's work is instrumental in advancing therapeutic options for conditions such as narcolepsy.

Latest Patents

Fujimoto's latest patents include a substituted piperidine compound and a heterocyclic compound, both of which exhibit orexin type 2 receptor agonist activity. The substituted piperidine compound is designed to serve as a prophylactic or therapeutic agent for narcolepsy. Similarly, the heterocyclic compound is also aimed at providing treatment options for this condition. Both compounds are represented by specific formulas, as detailed in their respective patent descriptions.

Career Highlights

Fujimoto is currently associated with Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work at Takeda has allowed him to focus on innovative solutions that address critical health issues. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Fujimoto has collaborated with notable colleagues, including Kentaro Rikimaru and Hiromichi Sugimoto. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of groundbreaking therapeutic agents.

Conclusion

Tatsuhiko Fujimoto's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of narcolepsy and other related conditions.

Profile summary based on public USPTO records.